Ceramide participates in cell programmed death induced by Type II anti-CD20 mAb.
10.11817/j.issn.1672-7347.2015.12.002
- Author:
Yan HUANG
1
;
Sun WU
2
;
Yuan ZHANG
2
;
Youmei ZI
2
;
Man YANG
2
;
Yan GUO
2
;
Lingxiu ZHANG
2
;
Lihua WANG
2
Author Information
1. Department of Hematology, First Affiliated Hospital of Xinxiang Medical College, Weihui Henan 453100, China huangydoctor@163.com.
2. Department of Hematology, First Affiliated Hospital of Xinxiang Medical College, Weihui Henan 453100, China.
- Publication Type:Journal Article
- MeSH:
Amino Acid Chloromethyl Ketones;
Apoptosis;
drug effects;
Cell Line, Tumor;
drug effects;
Humans;
Lymphoma, Non-Hodgkin;
Rituximab;
pharmacology;
Sphingosine;
analogs & derivatives;
pharmacology
- From:
Journal of Central South University(Medical Sciences)
2015;40(12):1292-1297
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To explore the exact mechanisms of programmed cell death (PCD) induced by Type II anti-CD20 mAb in CD20+ non-Hodgkin lymphoma (NHL) cells, and to provide theoretical basis for anti-tumor ability of new CD20 mAb.
METHODS:After incubation with Rituximab (a Type I anti-CD20 mAb) and Tositumomab (a Type II anti-CD20 mAb), Raji cells were stained by annexin V & propidium iodide (PI). The ratio of programmed death cells were measured by two channel flow cytometry (FCM). Before the treatment of anti-CD20 mAbs, Raji cells was incubated with a caspase inhibitor carbobenzoxy-valyl-alanyl-aspartyl-[O-methyl]- fluoromethylketone (Z-VAD-FMK) and a dihydroceramide synthase inhibitor fumonisin B1 (FB1) for 30 minutes to assess their inhibitory effect on PCD. High performance liquid chromatography (HPLC) was utilized to compare the ratio of programmed death cells between the pretreatment group (treated by Rituximab and Tositumomab) and the non-pretreatment group. The anti-CD20 mAbs-treated Raji cells were collected, and the ceramide levels in the Raji cells in the different pretreatment groups were also examined by HPLC, and the inhibitory effect of FB1 on the changes of ceramide levels in the Raji cells was measured. The Raji cells were incubated with different concentration C2-ceramide, C2-Ceramide-induced PCD was also evaluated by annexin V & PI staining after 16 hours.
RESULTS:Tositumomab (10 µg/mL) but not Rituximab (10 µg/mL) can induce significant PCD (28.6±4.2)% in Raji cells, with significant difference (t=26.48, P<0.01), which cannot be blocked by Z-VAD-FMK with a concentration range from 10 to 30 µmol/L (F=3.01, P>0.05). The cellular ceramide levels in Raji cells were significantly elevated after the treatment of Tositumomab (t=28.48, P<0.01). C2-ceramide can significantly induce PCD in Raji cells in a dose-dependent manner with a concentration range from 5 to 40 µmol/L (F=2.71, P>0.05). The dihydroceramide synthase inhibitor FB1 can significantly inhibit the elevated cellular ceramide levels (F=20.18, P<0.01) and cell programmed death induced by Tositumomab (F=17.02, P<0.01).
CONCLUSION:Type II but not Type I anti-CD20 mAbs can induce caspase independent PCD in CD20+ NHL cells through the elevation of cellular ceramide levels. The PCD is not associated with classic caspase pathway.
